A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours

Molecular Partners AG4 个研究点分布在 3 个国家目标入组 58 人开始时间: 2014年7月最近更新: 2019年8月7日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Molecular Partners AG
入组人数: 58
试验地点: 4
主要终点: Frequency of adverse events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This research study is looking at a new DARPin® drug candidate, called MP0250. There is evidence from preclinical studies that MP0250 may be effective in the treatment of cancer. This is the first study of MP0250 in humans and its main purpose is to test its safety and tolerability in patients with cancer. This study will also examine how the drug is changed by and removed from the body and look for indicators that the drug may be effective against cancer. This study will test several different dose levels of the study drug to determine the safety and tolerability profile of the drug.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female ≥ 18 years
•Histologically confirmed and documented advanced or metastatic solid tumour refractory to at least 1 prior regimen of standard treatment or for which no curative therapy is available and for whom MP0250 is a reasonable option
•Progressive or stable disease documented radiologically in the 4 weeks prior to screening
•Presence of a measurable tumour or a tumour evaluable per RECIST v1.1
•ECOG performance status ≤ 1
•Life expectancy ≥ 12 weeks
•Adequate haematological function prior to first dose, defined as:
•Absolute neutrophils count ≥ 1500 cells/μL
•Haemoglobin ≥ 9 g/dL
•Platelet count > 100,000/μL
•Prothrombin time or partial thromboplastin time < 1.2 x ULN
•Adequate renal function prior to first dose, defined as either
•Serum creatinine < 1.5 mg/dL or
•Serum creatinine clearance ≥ 50 mL/min/m2 (by Cockroft-Gault equation)
•Adequate hepatic function prior to first dose, defined as
•Total bilirubin ≤ 1.5 x ULN
•AST/ALT ≤ 2.5 x ULN, or ≤ 5 x ULN if known hepatic metastases
•Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5 x ULN if known hepatic or bone metastases
•Female patients with a negative pregnancy test result at screening and baseline

排除标准

•Female patients pregnant or breast-feeding
•Haematological malignancies or other secondary malignancy, that is currently clinically significant or requires active intervention
•Known untreated or symptomatic brain metastases
•Predominantly squamous non-small cell lung carcinoma
•Anti-tumour treatment within 4 weeks of the first infusion of MP0250, such as chemotherapy, experimental or targeted therapy, biologics, hormonal therapy and radiotherapy. The anti-tumour treatments below need longer wash-out periods and must not be given within the indicated weeks of the first infusion of MP0250:
•i. Nitrosoureas: 6 weeks ii. Monoclonal antibodies: 8 weeks
•Exceptions: the following anti-tumour treatments are allowed as indicated i. Palliative radiation to bone metastases to relieve bone pain ii. Standard of care treatment such as bone modifying agents (i.e. bisphosphonates), denosumab, maintenance hormonal therapy for metastatic prostate and breast cancers, hormone-replacement therapy, and oral contraceptives
•Presence of residual toxicities of CTC-AE Grade ≥ 2 after prior anti-tumour therapy at screening. Except meeting other exclusion criteria, grade 1 toxicities related to previous treatments are acceptable at the time of the first infusion of MP0250, as well as Grade 2 alopecia
•Exclusion criterion removed
•Major surgical procedures, open biopsy or significant traumatic injury within 4 weeks of first dose or anticipation of major surgical procedure during the course of the study, core biopsy or minor surgical procedures within 1 week of first dose
•Serious non-healing wound, active ulcer or untreated bone fracture
•Proteinuria at screening as defined by ≥ 1+ on urinalysis dipstick, confirmed by ≥ 1g in 24h urinalysis
•Uncontrolled hypertension or any other serious cardiovascular or cardiac condition as judged by the investigator
•Severe or uncontrolled renal insufficiency

研究组 & 干预措施

MP0250

Experimental

see section "intervention description" below

干预措施: MP0250 (Drug)

结局指标

主要结局

Frequency of adverse events

时间窗: From inclusion up to week 56

Nature of adverse events

时间窗: From inclusion up to week 56

Severity of adverse events

时间窗: From inclusion up to week 56

Blood chemistry values